Studies like LEADER and SUSTAIN-6 have shown that GLP-1 receptor agonists, such as semaglutide and liraglutide, reduce the risk of major adverse cardiovascular events (MACE), which include heart attack, stroke, and cardiovascular death, in individuals with type-2 diabetes. This evidence concerns the gene GLP1R and Stroke.